Stifel has revised its price target for Core Laboratories (CLB, Financial), reducing it from $19 to $15 while maintaining a Hold rating on the company's shares. This adjustment comes as part of the firm's preparations for the upcoming first-quarter earnings season. Stifel's analysts have updated their financial models for the oilfield services and equipment sector, projecting slightly lower Q1 activity levels than previously anticipated.
The revised outlook signals a more cautious stance in the near term, as analysts consider potential impacts on the industry's performance. Core Laboratories, known for its role within the oilfield services sector, is closely watched by investors as the company navigates these adjusted expectations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Core Laboratories Inc (CLB, Financial) is $16.80 with a high estimate of $24.00 and a low estimate of $11.00. The average target implies an upside of 38.27% from the current price of $12.15. More detailed estimate data can be found on the Core Laboratories Inc (CLB) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Core Laboratories Inc's (CLB, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Core Laboratories Inc (CLB, Financial) in one year is $21.47, suggesting a upside of 76.71% from the current price of $12.15. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Core Laboratories Inc (CLB) Summary page.
